Topic summary

Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold?

Compounds › Tirzepatide SURMOUNT programme SURPASS programme effect size tirzepatide

This is a generated summary. It shows the 5 most-liked posts from a topic of 12, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

h.mbekiTL22 Oct 2025#3

taper_table, post #1: Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? The question about Tirzepatide molecular mass that I actually want answered is the second one below. The first is context and I have kept it short. Both are stated with units, and… Go to post

On identity: the monoisotopic mass is close to 4813.5 Da and the electrospray series usually shows the 3+ and 4+ states most strongly at ordinary concentrations. A report that shows only a single charge state is worth a question.

The evidence for this is thinner than the way I have phrased it suggests.

11 likes in reply to #1 10mo

k.radichTL216 Oct 2025#4

Answering the question the opening post raises rather than the one it answers.

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

23 likes 9mo

b.vestergaardTL26 Dec 2025#8

m.coelho, post #5: Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound. That has been true for the… Go to post

This settles it for me, at least until somebody posts a reason it should not.

17 likes in reply to #5 8mo

ch.correiaTL218 Dec 2025#9

The published pharmacokinetics show dose proportionality across the studied range, which means dose arithmetic behaves the way you would naively expect. That is not true of every compound and it is worth knowing which ones it is true of.

That is what I would do. It may not be what is correct.

32 likes 7mo

j.nascimentoTL29 Jan 2026#11

Reading back through, this was answered upthread and I missed it. My fault.

7 likes 7mo

Read the full topic (12 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide SURMOUNT programme randomised trial effect size Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Reading back through what has been written here…		2	3.8k	10mo
SURPASS-2 and the comparator dose question that will not go away Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about SURPASS-2.…	+101	111	1.5k	18mo
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Compounds › Tirzepatide tirzepatide SURPASS programme SURMOUNT programme effect size Solved Tirzepatide's shorter half-life and its one practical consequence Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…	+130	137	11k	19mo
Why tirzepatide titration schedules have more steps than semaglutide's Compounds › Tirzepatide SURMOUNT programme SURPASS programme randomised trial tirzepatide Solved Wiki Asking directly, because I could not find a straight answer: Why tirzepatide titration schedules have more steps than semaglutide's I have spent a fortnight trying to pin tirzepatide titration schedules down…		4	8.4k	7mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide tirzepatide SURPASS programme SURMOUNT programme effect size Solved What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to know what…	+16	20	23k	19h

Related topics — sharing the tags SURMOUNT programme, SURPASS programme, effect size

Topic	Participants	Replies	Views	Activity
Revisiting: The arithmetic of an intermediate dose between two label steps Practice › Dosing & titration titration worked example dose reduction tirzepatide Revisiting: The arithmetic of an intermediate dose between two label steps Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…	+41	45	808	2mo
An 18-month record including the parts that went badly Outcomes › Progress reports data table long read effect size DXA An 18-month record including the parts that went badly — setting out what I have, and where I think it stops being reliable. Asking about 18-month record on behalf of the question I keep seeing asked badly,…	+77	81	17k	12h
Follow-up: Where the four-week escalation interval comes from, and what it is not Practice › Dosing & titration tirzepatide dose reduction worked example missed dose Wiki Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about four-week escalation…	+131	147	47k	18mo
Risk-of-bias tools and the judgement they conceal Evidence › Meta-analyses meta-analysis heterogeneity publication bias effect size Wiki Risk-of-bias tools and the judgement they conceal Writing it up because I had to work it out twice and would rather nobody else did. I have spent a fortnight trying to pin risk-of-bias tools down and I want…	+8	12	21k	11mo
Reading SURMOUNT-1 without the press release — one year on Compounds › Tirzepatide effect size SURPASS programme randomised trial Solved Closed Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on Reading SURMOUNT-1…	+45	50	7.6k	5mo